Qbrexza expiry date?

When does Qbrexza’s main patent run out?
The key U.S. patent covering Qbrexza (tirbanibulin) expires on February 28, 2025. This is the earliest date at which competitors could potentially develop and market generic versions that do not infringe the core claim of the original patent.[1]

What does that mean for pricing and biosimilar competition?
Once the patent expires, the brand‑name manufacturer is no longer legally barred from allowing other companies to produce biosimilar or generic versions, provided they meet FDA approval. This can drive down costs and increase patient access, though the impact may be tempered by additional, still‑valid patents that cover formulations or methods of use.[2]

Are there any other patents that still protect the drug?
Yes. Besides the main composition‑of‑matter patent, Qbrexza is covered by several secondary patents, including those that protect the specific ointment formulation, excipients, and application method. Some of these expire later than 2025, offering continued protection for those aspects of the product.[3]

Will the brand still be on the market after 2025?
The brand is expected to remain available. While the core patent ends in 2025, the company can still rely on other patents and regulatory exclusivities. Additionally, the drug’s FDA exclusivity period extends until 2026, which provides a limited window of market protection beyond the primary patent expiry.[4]

When does the FDA exclusivity period end?
Qbrexza’s FDA exclusivity, granted at the time of approval (2019), expires on January 2, 2026. After that, the drug may be subject to generic entry regardless of remaining patents, unless other intellectual‑property barriers persist.[5]

Key Takeaway
- Primary patent: February 28, 2025
- Additional patents: up to or beyond 2026
- FDA exclusivity: January 2, 2026

For detailed patent listings and dates, see DrugPatentWatch’s Qbrexza page.

Sources
[1] https://www.drugpatentwatch.com
[2] https://www.drugpatentwatch.com
[3] https://www.drugpatentwatch.com
[4] https://www.drugpatentwatch.com
[5] https://www.drugpatentwatch.com